

Antisense Bcl-2 Oligodeoxynucleotides Inhibit Progression to Androgen-Independence after Castration in the Shionogi Tumor Model¹

Hideaki Miyake, Anthony Tolcher, and Martin E. Gleave²

The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia V6H 3Z6, [H. M., M. E. G.]; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6 [A. T.]; and Division of Urology, University of British Columbia, Vancouver, British Columbia V5Z 3J5 [M. E. G.], Canada

ABSTRACT

Progression to androgen-independence remains the main obstacle to improving survival for patients with advanced prostate cancer. Although Bcl-2 expression in normal prostatic epithelial cells is low or absent, Bcl-2 is highly up-regulated in prostate cancer cells after androgen withdrawal and during progression to androgen-independence. Here, we test the efficacy of antisense Bcl-2 oligodeoxynucleotide (ODN) therapy administered adjuvantly after castration to delay time to androgen-independent recurrence in the androgen-dependent mouse Shionogi tumor model. Treatment of Shionogi tumor cells *in vitro* with antisense Bcl-2 ODN inhibited Bcl-2 expression in a dose-dependent and sequence-specific manner. Systemic administration of antisense Bcl-2 ODN in mice bearing Shionogi tumors beginning 1 day postcastration resulted in a more rapid regression of tumors and a significant delay of emergence of androgen-independent recurrent tumors. Furthermore, despite significant reduction of Bcl-2 expression in tumor tissues, antisense Bcl-2 ODN had no effect on Bcl-2 expression in normal mouse organs. These findings illustrate the potential utility of antisense Bcl-2 therapy for prostate cancer in an adjuvant setting with androgen ablation.

INTRODUCTION

No therapy exists that is superior to androgen ablation in patients with advanced prostate cancer. Approximately 80% of patients achieve symptomatic and/or objective response after androgen ablation; however, progression to androgen-independence ultimately occurs and remains the main obstacle to improving the survival and quality of life in this disease (1). To date, new nonhormonal therapies have been evaluated in patients with hormone refractory disease. When used in this end-stage setting, no nonhormonal agents have improved survival (2). A more rational strategy, therefore, would involve earlier application of novel agents to delay the emergence of the AI phenotype.

bcl-2, first recognized as the proto-oncogene translocated to the immunoglobulin heavy-chain locus in human B-cell lymphoma cells, is the prototype of a novel class of oncogenes that contributes to neoplastic progression, not by accelerating cell proliferation but rather by enhancing tumor cell survival through the inhibition of apoptosis (3). In prostate cancer, experimental and clinical observations strongly suggest that Bcl-2 plays a critical role in the progression to androgen-independence through the inhibition of apoptotic cell death precipitated by androgen ablation (4–9). Bcl-2 overexpression is also associated with resistance to several cytotoxic chemotherapies and radiotherapy (6, 7, 9).

The controlled study of the complex molecular processes associated with AI progression has been difficult because there is no ideal animal model that mimics the clinical course of the disease in men. The AD Shionogi mouse mammary carcinoma model is particularly useful to

assess the influence of androgen ablation on several molecular events during AI progression, including gene expression associated with apoptotic cell death. In this model, AD tumors in intact mice undergo complete regression after androgen withdrawal, but rapidly growing AI tumors recur after 1 month in a highly reproducible manner (10).

Antisense ODNs³ are chemically modified stretches of single-stranded DNA that are complementary to mRNA regions of a target gene and effectively inhibit gene expression by forming RNA/DNA duplexes (11). Phosphorothioate ODNs are stabilized to resist nucleic acid digestion by substituting one of the nonbridging phosphorus oxygens of DNA with a sulfur. Recently, several antisense ODNs specifically targeted against genes involved in neoplastic progression have been evaluated both *in vitro* and *in vivo* as potential therapeutic agents (12–15). In the present study, based on the accumulating evidence implicating Bcl-2 in AI progression, we tested whether the adjuvant use of antisense Bcl-2 ODN with androgen ablation enhances castration-induced apoptosis and delays progression to AI in the Shionogi tumor model.

MATERIALS AND METHODS

Antisense Bcl-2 ODN. Phosphorothioate ODNs used in this study were generously supplied by Dr. Brett P. Monia at ISIS Pharmaceuticals (Carlsbad, CA). The sequences of antisense Bcl-2 ODN corresponding to the mouse *bcl-2* translation initiation site were 5'-TCTCCCGCTTGCGCCAT-3'. Two base Bcl-2 mismatch ODNs (5'-TCTCCCGGCATGTGCCAT-3') were used as control.

Shionogi Tumor Growth. The Toronto subline of the transplantable SC-115 AD mouse mammary carcinoma (16) was used in all of the experiments. Shionogi tumor cells were maintained in DMEM (Life Technologies, Inc., Gaithersburg, MD) supplemented with 5% heat-inactivated FCS. For *in vivo* study, approximately 5×10^6 cells of the Shionogi carcinoma were injected s.c. into adult male DD/S strain mice. When Shionogi tumors became 1 to 2 cm in diameter, usually 2–3 weeks after injection, castration was performed through an abdominal incision under methoxyflurane anesthesia. Details of the maintenance of mice, tumor stock, and operative procedures were described previously (17).

Treatment of Cells with ODN. Lipofectin, a cationic lipid (Life Technologies, Inc., Gaithersburg, MD) was used to increase the ODN uptake of cells. Shionogi cells were treated with various concentrations of ODN after a preincubation for 20 min with 4 μ g/ml lipofectin in serum-free OPTI-MEM (Life Technologies, Inc.). Four h after the beginning of the incubation, the medium containing ODNs and lipofectin was replaced with the standard culture medium described above.

Northern Blot Analysis. Total RNA was isolated from cultured Shionogi tumor cells and Shionogi tumor tissues by the acid-guanidium thiocyanate-phenol-chloroform method. Poly(A)⁺ mRNA was then purified from total RNA using oligodeoxythymidylate cellulose (Pharmacia Biotech Inc., Uppsala, Sweden). Five μ g of poly(A)⁺ mRNA from each sample was subjected to electrophoresis on 1.2% agarose-formaldehyde gels and transferred to nylon membranes overnight according to standard procedure (18). The RNA blots were hybridized with a mouse Bcl-2 cDNA probe labeled with [³²P]dCTP by random primer labeling. After stripping, the membranes were rehybridized

³ The abbreviations used are: ODN, oligodeoxynucleotide; AD, androgen-dependent; AI, androgen-independent; PARP, poly(ADP-ribose) polymerase; G3PDH, glyceraldehyde-3-phosphate dehydrogenase.

Received 2/9/99; accepted 6/16/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by Grant 009002 from the National Cancer Institute of Canada.

² To whom requests for reprints should be addressed, at Division of Urology, University of British Columbia, d-9, 2733 Heather Street, Vancouver, BC V5Z 3J5, Canada.

with a mouse G3PDH cDNA probe. The density of bands for Bcl-2 was normalized against that of G3PDH by densitometric analysis.

Western Blot Analysis. Samples containing equal amounts of protein (15 μ g) from lysates of the cultured Shionogi cells and Shionogi tumors were electrophoresed on a SDS-polyacrylamide gel and transferred to a nitrocellulose filter. The filters were blocked in PBS containing 5% nonfat milk powder at 4°C overnight and then incubated for 1 h with a 1:200-diluted C-2, an antihuman Bcl-2 mouse monoclonal antibody that reacts with mouse Bcl-2 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), 1:10,000-diluted MAB065, an antirat β -tubulin mouse monoclonal antibody (Chemicon International Inc., Temecula, CA) that reacts with mouse β -tubulin, or 1:600-diluted C2-10, an antihuman PARP mouse monoclonal antibody that reacts with mouse PARP (Pharmingen, Mississauga, Ontario, Canada). The filters were then incubated for 30 min with horseradish peroxidase-conjugated antimouse IgG antibody (Amersham Life Science, Arlington Heights, IL), and specific proteins were detected using an enhanced chemiluminescence Western blotting analysis system (Amersham Life Science).

Assessment of *in Vivo* Tumor Growth. Male DD/S mice bearing Shionogi tumor were castrated and randomly selected for treatment with antisense Bcl-2 *versus* mismatch control ODN. Each experimental group consisted of seven mice. One day after castration, 12.5 mg/kg antisense Bcl-2 or mismatch control ODNs, diluted with PBS, were administered by i.p. injection into each mouse once daily for 40 days. Tumor volume was measured twice weekly and calculated by the formula, length \times width \times depth \times 0.5236 (19). Data points were reported as average tumor volumes \pm SD.

RESULTS

Changes of Bcl-2 mRNA Expression in the Shionogi Tumor Model. Northern blot analyses were used to characterize changes in Bcl-2 mRNA expression in AD intact tumors before castration, in regressing tumors 4 and 7 days after castration, and in AI recurrent tumors 28 days after castration. As shown in Fig. 1, A and B, Bcl-2 mRNA expression was up-regulated 5-fold and 3-fold 4 and 7 days after castration, respectively, and was maintained at 2-fold higher




Fig. 1. Changes of Bcl-2 mRNA expression in the Shionogi tumor model. A, Shionogi tumors were harvested before and at several time points after castration; poly(A)⁺ RNA was extracted from each tumor tissue and analyzed for Bcl-2 and G3PDH levels by Northern blotting. Lane 1, AD tumor before castration; Lane 2, regressing tumor 4 days after castration; Lane 3, regressing tumor 7 days after castration; Lane 4, AI recurrent tumor 28 days after castration. B, quantitative analysis of Bcl-2 mRNA levels after normalization to G3PDH mRNA levels in the Shionogi tumor model was performed by using laser densitometer. Each column, the mean value with SD (bar).

levels in AI tumors than in AD intact tumors before castration. The pattern of Bcl-2 up-regulation in the Shionogi tumor model during AI progression is similar to that in the clinical disease (8, 9) and, therefore, supports the use of this model to evaluate the effect of adjuvant antisense Bcl-2 therapy on progression to AI.

Antisense ODN-mediated Inhibition of Bcl-2 Expression in Shionogi Tumor Cells. The effect of treatment with antisense Bcl-2 ODN on Bcl-2 mRNA expression in Shionogi tumor cells was initially evaluated by Northern blot analysis. As shown in Fig. 2, A and B, daily treatment of Shionogi tumor cells with antisense Bcl-2 ODNs (50, 100, 500, or 1000 nM) for 2 days reduced Bcl-2 mRNA levels by 5, 25, 77, or 94%, respectively. In contrast, Bcl-2 mRNA expression was not affected by the two-base mismatch control ODNs at any of the used concentrations.

To further analyze the specificity of antisense Bcl-2 ODNs, Northern blotting was performed on other apoptosis-associated genes, *bax* and *bcl-x_L*, both of which share significant sequence homology with *bcl-2*. Antisense Bcl-2 ODNs markedly reduced Bcl-2 mRNA expression, but no effects were observed on Bax and Bcl-x_L expression levels (Fig. 2C). These findings demonstrate that antisense Bcl-2 ODNs used in these studies do not effect expression of related isotypes.

To determine whether the decrease in Bcl-2 mRNA levels induced by antisense ODN is accompanied by a corresponding decrease in protein levels, Western blot analysis was used to measure changes in Bcl-2 protein levels in Shionogi tumor cells after daily treatment with antisense Bcl-2 ODNs for 4 consecutive days. Dose-dependent inhibition of Bcl-2 protein levels was observed with antisense Bcl-2 but not with mismatch control ODN treatment (Fig. 3).

Delayed AI Progression of Shionogi Tumors by Antisense Bcl-2 ODN Treatment. Male mice bearing Shionogi tumors were castrated 2 to 3 weeks after tumor implantation, at which time tumors were 1 to 2 cm in diameter, and randomly selected for treatment with antisense Bcl-2 *versus* mismatch control ODN. Mean tumor volume was similar in both groups at the beginning of ODN treatment. Beginning 1 day after castration, 12.5 mg/kg ODN was administered once daily by i.p. injection for 40 days. As shown in Fig. 4, Shionogi tumors regressed faster and complete regression occurred earlier in mice treated with antisense Bcl-2 ODN compared to those treated with mismatch control ODN. Furthermore, antisense Bcl-2 ODN treatment significantly delayed recurrence of AI tumors compared to mismatch control ODN treatment. During an observation period of 50 days postcastration, AI tumors recurred in 5 of 7 mice after a median of 44 days in antisense Bcl-2 ODN treatment group, while AI tumors recurred in all of the mice after a median of 29 days in mismatch control ODN treatment group. Under the experimental conditions used in the above *in vivo* experiment, no side effects associated with antisense Bcl-2 or mismatch control ODN treatment were observed.

We then examined the effects of *in vivo* ODN treatment on Bcl-2 mRNA expression in Shionogi tumors by Northern blotting. In this experiment, beginning 1 day postcastration, each of three tumor-bearing mice were given 12.5 mg/kg antisense Bcl-2 or mismatch control ODN i.p. once daily, and tumor tissues were harvested for RNA extraction 4 days after castration. Antisense Bcl-2 ODN resulted in a 72% reduction in Bcl-2 mRNA levels in Shionogi tumors compared with mismatch control ODN-treated tumors (Fig. 5, A and B).

To determine whether more rapid regression of antisense ODN-treated tumors resulted from an earlier onset of castration-induced apoptosis, Western blotting of tumor tissues was used to measure the cleavage of PARP protein, a substrate of the caspase activated during the final process of apoptotic execution (20). Proteins were extracted 4 days postcastration from each of three Shionogi tumors in mice given antisense Bcl-2 or mismatch control ODNs under the same

treatment schedule described above. The M_r 116,000 intact form of PARP was observed in both antisense Bcl-2 ODN-treated and mismatch control ODN-treated Shionogi tumors, whereas the M_r 85,000 PARP cleavage fragment was clearly detectable only in antisense Bcl-2 ODN-treated Shionogi tumors (Fig. 6).

We also evaluated changes in Bcl-2 mRNA levels in various normal mouse organs reported to express detectable levels of Bcl-2 mRNA (21). Shionogi tumors, spleen, thymus, and brain were harvested 4 days postcastration for RNA extraction from mice given antisense Bcl-2 or mismatch control ODN under the same treatment schedule described above. Although Bcl-2 mRNA expression was significantly lower in tumor tissues, antisense Bcl-2 ODN had no effect on Bcl-2 expression levels in several normal organs, including spleen, thymus, and brain (Fig. 7).




Fig. 2. Sequence-specific inhibition of Bcl-2 mRNA by antisense Bcl-2 ODNs in Shionogi tumor cells. In A, Shionogi tumor cells were treated daily with various concentrations of antisense Bcl-2 ODN (TCTCCCGGCT-TGCGCCAT) or a two-base Bcl-2 mismatch ODN (TCTCCCGGCATGTGCCAT) as a control for 2 days; poly(A)⁺ RNA was extracted from culture cells and analyzed for Bcl-2 and G3PDH levels by Northern blotting. No Tx, untreated cells. B, quantitative analysis of Bcl-2 mRNA levels—after the normalization to G3PDH mRNA levels in Shionogi tumor cells after treatment with various concentrations of antisense Bcl-2 or mismatch control ODNs—was performed by using laser densitometry. Each point, the mean of triplicate analyses with SD. C, Northern blot analysis of Bcl-2, Bax, Bcl-xL, and G3PDH mRNA levels in Shionogi tumor cells daily, treated with 500 nM antisense Bcl-2 or mismatch control ODNs for 2 days, was performed. No Tx, untreated cells.




Fig. 3. Inhibition of Bcl-2 protein by antisense Bcl-2 ODN in Shionogi tumor cells. Shionogi tumor cells were treated with various concentrations of antisense Bcl-2 or mismatch control ODNs once daily for 4 days, protein was extracted from culture cells, and Bcl-2 and β-tubulin protein levels were analyzed by Western blotting. No Tx, untreated cells.




Fig. 4. Effects of antisense Bcl-2 ODN administration on Shionogi tumor growth. Beginning 1 day postcastration, 12.5 mg/kg antisense Bcl-2 or mismatch control ODNs were injected i.p. once daily for 40 days into each mouse bearing Shionogi tumors. Tumor volume was measured twice weekly and calculated by the formula, length × width × depth × 0.5236. Each point, the mean tumor volume in each experimental group containing seven mice, with SD.

DISCUSSION

Previous studies have identified a strong association between Bcl-2 and prostate cancer progression, especially with androgen-independence (4–9). For example, the introduction of *bcl-2* cDNA into LNCaP prostate cancer cells increases their *in vivo* tumorigenic potential and resistance to apoptosis induced by androgen ablation (4), and Bcl-2 protein expression is higher in LNCaP cells that have metastasized in nude mice (5). Furthermore, increased expression of Bcl-2 in prostate cancer has been correlated with poor prognosis (6) and the emergence of AI tumors (8). Collectively, these findings suggest that the inhibition of Bcl-2 up-regulation precipitated by androgen ablation may enhance castration-induced apoptosis and delay AI progression of prostate cancer.

Antisense ODN therapy offers one strategy to specifically target *bcl-2* gene expression. Phosphorothioate ODNs are water-soluble, stable agents manufactured to resist nuclease digestion. After parental administration, phosphorothioate ODNs become associated with high-capacity, low-affinity serum-binding proteins (22). Recent reports have shown that antisense Bcl-2 ODNs induce apoptosis in Bcl-2 positive small cell lung cancer cell lines *in vitro* (14) and increase chemosensitivity of melanoma cells *in vitro* and *in vivo* (15). Hammerhead anti-Bcl-2 ribozyme treatment of LNCaP cells reduces Bcl-2 levels and induces apoptosis in low-Bcl-2-expressing LNCaP variants *in vitro* (23). Taken together, these preclinical data support the hypothesis that targeting *bcl-2* gene expression using antisense ODNs is a valid therapeutic strategy. The objectives of our studies were to evaluate the effects of androgen ablation on Bcl-2 expression




Fig. 5. Effects of antisense Bcl-2 ODN administration on Bcl-2 mRNA levels in Shionogi tumors by day 4 postcastration. In A, 1 day postcastration, each of 3 Shionogi tumor-bearing mice were daily treated with antisense Bcl-2 or mismatch control ODNs at a dose of 12.5 mg/kg; poly(A)⁺ RNA was extracted from Shionogi tumors 4 days postcastration; and Bcl-2 and G3PDH mRNA levels were analyzed by Northern blotting. Lanes 1, 2, and 3, Shionogi tumors in mice given antisense Bcl-2 ODNs; Lanes 4, 5, and 6, Shionogi tumors in mice given mismatch control ODNs. B, quantitative analysis of Bcl-2 mRNA levels after normalization to G3PDH mRNA levels in Shionogi tumors after treatment with antisense Bcl-2 or mismatch control ODNs was performed by using laser densitometer. Each column, the mean value with SD.




Fig. 6. Effects of antisense Bcl-2 ODN administration on the cleavage of PARP in Shionogi tumors by day 4 postcastration. One day postcastration, each of three Shionogi tumor-bearing mice were treated daily with antisense Bcl-2 or mismatch control ODNs at a dose of 12.5 mg/kg; proteins extracted from Shionogi tumors 4 days postcastration were analyzed by Western blotting with a PARP-specific antibody. Uncleaved intact PARP, $M_r = 116,000$; cleaved PARP, $M_r = 85,000$. Lanes 1, 2, and 3, Shionogi tumors in mice given antisense Bcl-2 ODNs; Lanes 4, 5, and 6, Shionogi tumors in mice given mismatch control ODNs.

in Shionogi tumors after castration and during AI progression and to determine whether the combination of antisense Bcl-2 ODN and androgen withdrawal therapy could delay time to AI progression.

The Shionogi tumor model is a xenograft of an AD mouse mammary carcinoma that grows s.c. in male syngeneic hosts. Shionogi tumor cells are highly tumorigenic and locally invasive. Androgen withdrawal precipitates apoptosis and tumor regression in a highly reproducible manner. Despite complete regression after castration, rapidly growing AI Shionogi tumors invariably recur after 1 month, which provides a reliable end point to evaluate agents that can delay time to AI progression (10). We demonstrated by Northern blot analysis that Bcl-2 mRNA is up-regulated in Shionogi tumors after castration and in AI recurrent tumors. Changes in Bcl-2 expression in human prostate cancer during AI progression is similar to that in the Shionogi tumor model (8, 9).

In this study, phosphorothioate antisense Bcl-2 ODN corresponding to the mouse *bcl-2* translation initiation site inhibited expression of Bcl-2 mRNA and protein in a dose-dependent manner. Sequence specificity was confirmed using a 2-base Bcl-2 mismatch ODN, which had no effects on Bcl-2 mRNA and protein expression in Shionogi

tumor cells. Furthermore, we demonstrated that antisense Bcl-2 ODNs decreased Bcl-2 expression in a target-specific manner; that is, the expression of other mRNAs, including related isotypes, Bax and Bcl-x_L, were not affected by antisense Bcl-2 ODN treatment.

In our *in vivo* experiments, administration of antisense Bcl-2 ODNs accelerated castration-induced tumor regression and delayed time to AI progression compared with that of mismatch control ODN. Similar to our *in vitro* treatments, *in vivo* treatment of mice bearing Shionogi tumors with antisense Bcl-2 ODN also inhibited the Bcl-2 mRNA expression. These findings illustrate that *in vivo* systemic administration of ODN can result in sequence-specific down-regulation of a target gene in tumor cells. Enhanced cleavage of PARP protein in Shionogi tumors by antisense Bcl-2 ODN suggests that *in vivo* inhibition of Bcl-2 expression results in the earlier induction of castration-induced apoptosis in tumor tissues.

The sequence-specificity of Bcl-2 mRNA suppression observed in these *in vitro* and *in vivo* studies supports an antisense mechanism of action for the antisense ODN, although additional therapeutically beneficial, sequence-independent, nonantisense interactions cannot be ruled out (24, 25). For example, nonspecific immunostimulation by phosphorothioate ODNs can occur via natural killer-cell activation (26). Phosphorothioate ODNs have also been shown to competitively inhibit a variety of nucleases and polymerases (27, 28) and to interact with heparin-binding growth factors (29). However, nonspecific *in vivo* activity was not observed in our studies using phosphorothioate mismatch control ODNs. Despite distinct sequence-specific Bcl-2 suppression and significant *in vivo* activity, a cytotoxic effect of antisense Bcl-2 ODN was not observed in Shionogi tumor cells *in vitro* (data not shown). Induction of apoptosis *in vitro* has been reported by other investigators after treatment with antisense Bcl-2 ODN (14, 15) or ribozyme (23). This discrepancy may result from varying sensitivity to specific apoptotic stimuli in different cell lines. Furthermore, the relative balance between death antagonists and death agonists after androgen withdrawal may differ under *in vitro* and *in vivo* conditions. Androgen-regulated gene expression and growth sensitivity in AD tissues is significantly altered when transferred to *in vitro* monolayer culture (10, 30).

Whether antisense ODNs targeted against a specific cellular regulatory molecule have toxic effects on nondiseased organs remains undefined. Because Bcl-2 plays a critical role in some normal organs including brain and thymus (31, 32), the effects of antisense Bcl-2 ODNs on Bcl-2 expression levels in these organs were examined in DD/S mice bearing Shionogi tumors. Despite the significant decrease in Bcl-2 expression in tumor tissues, Bcl-2 expression seemed unaffected by antisense ODN in the normal organs examined. Indeed, no side effects in either antisense Bcl-2 or mismatch control ODN




Fig. 7. Effects of antisense Bcl-2 ODN administration on Bcl-2 mRNA levels in normal organs. One day postcastration, Shionogi tumor-bearing mice were treated daily with antisense Bcl-2 or mismatch control ODNs at a dose of 12.5 mg/kg, poly(A)⁺ RNA was extracted from Shionogi tumor, spleen, thymus, and brain 4 days postcastration, and Bcl-2 and G3PDH mRNA levels were analyzed by Northern blotting.

treatment group in the present *in vivo* study were observed. Monia *et al.* reported reduced *C-raf* mRNA levels in mouse tissues after *in vivo* administration of antisense *C-raf* mRNA ODN; however, they also observed no significant toxicities resulting from these effects (12). A Phase I dose-escalation trial using antisense Bcl-2 ODNs in nine patients with lymphoma reported objective and subjective responses with no significant toxicity (33). These findings suggest that tumor tissues may be more sensitive to phosphorothioate ODN treatment compared with normal organs, possibly because of a preferential uptake of ODN in tumor tissues for reasons of biodistribution or increased membrane permeability.

To date, new nonhormonal therapies have been traditionally evaluated in patients with hormone-refractory disease, and, when used in this end-stage setting, none has demonstrated improved survival (2). A more rational strategy to delay emergence of the AI phenotype would initiate treatment earlier to enhance castration-induced apoptosis by targeting the adaptive changes in gene expression precipitated by androgen withdrawal rather than the conventional approach of treating patients with established hormone-refractory disease. The and appropriate timing of combination therapies, based on biological mechanism of progression and castration-induced changes in gene expression, may provide means to delay AI progression in a major way. The present study provides indirect evidence to further support a functional role for Bcl-2 in AI progression and demonstrates that the reduction of *bcl-2* gene expression by antisense Bcl-2 ODNs inhibits progression to androgen-independence in the Shionogi tumor model. This preclinical data provides support for clinical studies with antisense Bcl-2 ODNs used adjuvantly with androgen ablation in patients with prostate cancer.

ACKNOWLEDGMENTS

We thank Mary Bowden and Virginia Yago for their excellent technical assistance.

REFERENCES

1. Denis, L., and Murphy, G. P. Overview of Phase III trials on combined androgen treatment in patients with metastatic prostate cancer. *Cancer (Phila.)*, 72: 3888–3895, 1993.
2. Oh, W. K., and Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. *J. Urol.*, 160: 1220–1229, 1998.
3. Tsujimoto Y., and Croce, C. M. Analysis of the structure, transcripts, and protein products of *bcl-2*, the gene involved in human follicular lymphoma. *Proc. Natl. Acad. Sci. USA*, 83: 5214–5218, 1986.
4. Raffo, A. J., Periman, H., Chen, M. W., Streitman, J. S., and Buttyan, R. Overexpression of *bcl-2* protects prostate cancer cells from apoptosis *in vitro* and confers resistance to androgen depletion *in vivo*. *Cancer Res.*, 55: 4438–4445, 1995.
5. McConkey, D. J., Greene, G., and Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. *Cancer Res.*, 56: 5594–5599, 1996.
6. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Moul, J. W. Elevated levels of apoptosis regulatory proteins p53 and *bcl-2* are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. *J. Urol.*, 156: 1511–1516, 1996.
7. Grossfeld, G. D., Olumi, A. F., Connolly, J. A., Chew, K., Gibney, J., Bhargava, V., Waldman, F. M., and Carroll, P. R. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in K_i-67 labeling index, p53 and Bcl-2 immunoreactivity. *J. Urol.*, 159: 1437–1443, 1998.
8. McDonnell, T. J., Troncoco, P., Brisby, S. M., Logothesis, C. L., Chung, L. W. K., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the protooncogene *Bcl-2*

- in the prostate and its association with emergence of androgen-independent prostate cancer. *Cancer Res.*, 52: 6940–6944, 1992.
9. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Choplin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. *Am. J. Pathol.*, 143: 390–400, 1993.
 10. Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M., and Lawson, D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. *Cancer Res.*, 50: 2275–2282, 1990.
 11. Crooke, S. T. Therapeutic applications of oligonucleotides. *Annu. Rev. Pharmacol. Toxicol.*, 32: 329–376, 1993.
 12. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. *Nat. Med.*, 2: 668–675, 1996.
 13. Cucco, C., and Calabretta, B. *In vitro* and *in vivo* reversal of multidrug resistance in a human leukemia-resistant cell line by *mdr1* antisense oligodeoxynucleotides. *Cancer Res.*, 56: 4332–4337, 1996.
 14. Ziegler, A., Luedke, G. H., Fabbro, D., Altman, K. H., Stahel, R. A., and Zange-meister-Witke, U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. *J. Natl. Cancer Inst.*, 89: 1027–1036, 1997.
 15. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elisa, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. *bcl-2* antisense therapy chemosensitizes human melanoma in SCID mice. *Nat. Med.*, 4: 232–234, 1998.
 16. Rennie, P. S., Bruchovsky, N., Buttyan, R., and Cheng, H. Gene expression during the early phase of regression of the androgen-dependent Shionogi mouse mammary carcinoma. *Cancer Res.*, 48: 6309–6312, 1988.
 17. Bruchovsky, N., and Rennie, P. S. Classification of dependent and autonomous variants of Shionogi mammary carcinoma based on heterogeneous patterns of androgen binding. *Cell*, 13: 272–280, 1978.
 18. Gleave, M. E., Hsieh, J. T., Wu, H.-C., and Chung, L. W. K. Serum PSA levels in mice bearing human prostate LNCaP tumor are determined by tumor volume and endocrine and growth factors. *Cancer Res.*, 52: 1598–1605, 1992.
 19. Gleave, M. E., Hsieh, J. T., Gao, C., von Eschenbach, A. C., and Chung, L. W. K. Acceleration of human prostate carcinoma growth *in vivo* by factors produced by prostate and bone fibroblasts. *Cancer Res.*, 51: 3753–3761, 1991.
 20. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. *Nature (Lond.)*, 371: 346–347, 1994.
 21. Negrini, M., Silini, E., Kozak, C., Tsujimoto, Y., and Croce, C. M. Molecular analysis of *mbcl-2*: structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma. *Cell*, 49: 455–463, 1987.
 22. Saijo, Y., Perlaky, L., Wang, H., and Busch, H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. *Oncol. Res.*, 6: 243–249, 1994.
 23. Dorai, T., Olsson, C. A., Katz, A. E., and Buttyan, R. Development of a hammerhead ribozyme against *bcl-2*. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. *Prostate*, 32: 246–258, 1997.
 24. Stein, C. A., and Cheng, Y. C. Antisense oligonucleotides as therapeutic agents—is the bullet really magical? *Science (Washington DC)*, 261: 1004–1012, 1993.
 25. Stein, C. A. Does antisense exist? *Nat. Med.*, 1: 1119–1121, 1995.
 26. Wooldridge, J. E., Ballas, Z., Krieg, A. M., and Weiner, G. J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. *Blood*, 89: 2994–2998, 1997.
 27. Crooke, S. T., Lemonidis, K. M., Neilson, L., Griffey, R., Lesnik, E. A., and Monia, B. P. Kinetic characteristics of *Escherichia coli* RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. *Biochem. J.*, 312: 599–608, 1995.
 28. Gao, W. Y., Han, F. S., Storm, C., Egan, W., and Cheng, Y. C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. *Mol. Pharmacol.*, 41: 223–229, 1992.
 29. Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkison, J. L., and Stein, C. A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. *J. Biol. Chem.*, 270: 2620–2627, 1995.
 30. Hoehn, W., Schroeder, F. H., Riemann, J. F., Joebis, A. C., and Hermanek, P. Human prostatic adenocarcinoma: Some characteristics of a serially transplantable line in nude mice (PC82). *Prostate*, 1: 95–104, 1980.
 31. Chen D. F., Schneider, G. E., Martinou, J. C., and Tonegawa, S. Bcl-2 promotes regeneration of served axons in mammalian CNS. *Nature (Lond.)*, 385: 443–449, 1997.
 32. Williams, O., Norton, T., Halligey, M., Kioussis, D., and Brady, H. J. M. The action of Bax and *bcl-2* on T cell selection. *J. Exp. Med.*, 188: 1125–1133, 1998.
 33. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. *Lancet*, 349: 1137–1141, 1997.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Antisense Bcl-2 Oligodeoxynucleotides Inhibit Progression to Androgen-Independence after Castration in the Shionogi Tumor Model

Hideaki Miyake, Anthony Tolcher and Martin E. Gleave

Cancer Res 1999;59:4030-4034.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/59/16/4030>

Cited articles This article cites 31 articles, 14 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/59/16/4030.full#ref-list-1>

Citing articles This article has been cited by 32 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/59/16/4030.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/59/16/4030>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.